APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oligonucleotide Therapeutics

Many pharmaceutical companies were conducting research on oligonucleotide therapy, which employs chemically synthesized nucleotide-like small molecule drugs with potential specificity similar to that of therapeutic antibodies.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Many pharmaceutical companies were conducting research on oligonucleotide therapy, which employs chemically synthesized nucleotide-like small molecule drugs with potential specificity similar to that of therapeutic antibodies.

Although several types of oligonucleotide therapies exist, five of them are compared here, including the ones targeting nucleic acids (such as mRNA) or proteins, as well as others intended for stimulation of the immune system. DDS is generally used with oligonucleotide therapy, as it is difficult for these molecules to penetrate cell membrane when administered on their own.

Selected research

Market Structure

Global Oligonucleotide Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

31 December 2025182 pages

Choose your research edition.

Industry ResearchOligonucleotide Therapeutics Industry Research Report 2026111 pages · $2,950 USDIndustry Growth & TrendsGlobal Oligonucleotide Therapeutics Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Oligonucleotide Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oligonucleotide Therapeutics Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Oligonucleotide Therapeutics Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

Many pharmaceutical companies were conducting research on oligonucleotide therapy, which employs chemically synthesized nucleotide-like small molecule drugs with potential specificity similar to that of therapeutic antibodies.

Although several types of oligonucleotide therapies exist, five of them are compared here, including the ones targeting nucleic acids (such as mRNA) or proteins, as well as others intended for stimulation of the immune system. DDS is generally used with oligonucleotide therapy, as it is difficult for these molecules to penetrate cell membrane when administered on their own.

Biogen is the industry's biggest player, with more than 76 percent of 2018 revenue, followed by Sarepta Therapeutics and Jazz Pharmaceuticals, with 13.35 percent and 6.63 percent, respectively. North America and Europe are the most important regions, accounting for more than 80 percent of the combined income.

Read the full market overview

Report Includes

This report provides an overview of the global Oligonucleotide Therapeutics market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Oligonucleotide Therapeutics and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Oligonucleotide Therapeutics revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Oligonucleotide Therapeutics market size, projected growth trends, production technologies, key applications, and end-use industries.

Oligonucleotide Therapeutics Segment by Company

Biogen

Sarepta Therapeutics

Jazz Pharmaceuticals

Bausch & Lomb

Alnylam Pharmaceuticals

Dynavax Technologies

Kastle therapeutics

Akcea Therapeutics

Oligonucleotide Therapeutics Segment by Type

Antisense Oligonucleotide

Aptamer

Other

Oligonucleotide Therapeutics Segment by Application

Neuromuscular Diseases

ATTR

Hepatic VOD

Other

Oligonucleotide Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oligonucleotide Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oligonucleotide Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oligonucleotide Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Oligonucleotide Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Oligonucleotide Therapeutics industry.

Chapter 3: Detailed analysis of Oligonucleotide Therapeutics companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Oligonucleotide Therapeuticsrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Oligonucleotide Therapeutics Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Antisense Oligonucleotide Table 3. Key Players of Aptamer Table 4. Key Players of Other Table 4. Global Oligonucleotide Therapeutics Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Neuromuscular Diseases Table 6. Key Players of ATTR Table 7. Key Players of Hepatic VOD Table 8. Key Players of Other Table 9. Global Oligonucleotide Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 10. Global Oligonucleotide Therapeutics Market Size by Region (2021-2026) & (US$ Million) Table 11. Global Oligonucleotide Therapeutics Market Share by Region (2021-2026) Table 12. Global Oligonucleotide Therapeutics Market Size by Region (2027-2032) & (US$ Million) Table 13. Global Oligonucleotide Therapeutics Market Share by Region (2027-2032) Table 14. Oligonucleotide Therapeutics Industry Trends Table 15. Oligonucleotide Therapeutics Industry Drivers Table 16. Oligonucleotide Therapeutics Industry Opportunities and Challenges Table 17. Oligonucleotide Therapeutics Industry Restraints Table 18. Global Oligonucleotide Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 19. Global Oligonucleotide Therapeutics Revenue Market Share by Company (2021-2026) Table 20. Global Oligonucleotide Therapeutics Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 21. Global Oligonucleotide Therapeutics Key Company Head Office and Area Served Table 22. Global Oligonucleotide Therapeutics Company, Product Type & Application Table 23. Global Oligonucleotide Therapeutics Company Establishment Date Table 24. Global Company Market Concentration Ratio (CR5 and HHI) Table 25. Global Oligonucleotide Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 26. Global Oligonucleotide Therapeutics Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Oligonucleotide Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 28. Global Oligonucleotide Therapeutics Market Size by Type (2027-2032) & (US$ Million) Table 29. Global Oligonucleotide Therapeutics Revenue Market Share by Type (2021-2026) Table 30. Global Oligonucleotide Therapeutics Revenue Market Share by Type (2027-2032) Table 31. Global Oligonucleotide Therapeutics Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Oligonucleotide Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 33. Global Oligonucleotide Therapeutics Market Size by Application (2027-2032) & (US$ Million) Table 34. Global Oligonucleotide Therapeutics Revenue Market Share by Application (2021-2026) Table 35. Global Oligonucleotide Therapeutics Revenue Market Share by Application (2027-2032) Table 36. Biogen Company Information Table 37. Biogen Business Overview Table 38. Biogen Oligonucleotide Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Biogen Oligonucleotide Therapeutics Product Portfolio Table 40. Biogen Recent Development Table 41. Sarepta Therapeutics Company Information Table 42. Sarepta Therapeutics Business Overview Table 43. Sarepta Therapeutics Oligonucleotide Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Sarepta Therapeutics Oligonucleotide Therapeutics Product Portfolio Table 45. Sarepta Therapeutics Recent Development Table 46. Jazz Pharmaceuticals Company Information Table 47. Jazz Pharmaceuticals Business Overview Table 48. Jazz Pharmaceuticals Oligonucleotide Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Jazz Pharmaceuticals Oligonucleotide Therapeutics Product Portfolio Table 50. Jazz Pharmaceuticals Recent Development Table 51. Bausch & Lomb Company Information Table 52. Bausch & Lomb Business Overview Table 53. Bausch & Lomb Oligonucleotide Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Bausch & Lomb Oligonucleotide Therapeutics Product Portfolio Table 55. Bausch & Lomb Recent Development Table 56. Alnylam Pharmaceuticals Company Information Table 57. Alnylam Pharmaceuticals Business Overview Table 58. Alnylam Pharmaceuticals Oligonucleotide Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Alnylam Pharmaceuticals Oligonucleotide Therapeutics Product Portfolio Table 60. Alnylam Pharmaceuticals Recent Development Table 61. Dynavax Technologies Company Information Table 62. Dynavax Technologies Business Overview Table 63. Dynavax Technologies Oligonucleotide Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Dynavax Technologies Oligonucleotide Therapeutics Product Portfolio Table 65. Dynavax Technologies Recent Development Table 66. Kastle therapeutics Company Information Table 67. Kastle therapeutics Business Overview Table 68. Kastle therapeutics Oligonucleotide Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Kastle therapeutics Oligonucleotide Therapeutics Product Portfolio Table 70. Kastle therapeutics Recent Development Table 71. Akcea Therapeutics Company Information Table 72. Akcea Therapeutics Business Overview Table 73. Akcea Therapeutics Oligonucleotide Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Akcea Therapeutics Oligonucleotide Therapeutics Product Portfolio Table 75. Akcea Therapeutics Recent Development Table 76. North America Oligonucleotide Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 77. North America Oligonucleotide Therapeutics Market Size by Type (2027-2032) & (US$ Million) Table 78. North America Oligonucleotide Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 79. North America Oligonucleotide Therapeutics Market Size by Application (2027-2032) & (US$ Million) Table 80. North America Oligonucleotide Therapeutics Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 81. North America Oligonucleotide Therapeutics Market Size by Country (2021-2026) Table 82. North America Oligonucleotide Therapeutics Market Size by Country (2027-2032) Table 83. Europe Oligonucleotide Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 84. Europe Oligonucleotide Therapeutics Market Size by Type (2027-2032) & (US$ Million) Table 85. Europe Oligonucleotide Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 86. Europe Oligonucleotide Therapeutics Market Size by Application (2027-2032) & (US$ Million) Table 87. Europe Oligonucleotide Therapeutics Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 88. Europe Oligonucleotide Therapeutics Market Size by Country (2021-2026) Table 89. Europe Oligonucleotide Therapeutics Market Size by Country (2027-2032) Table 90. China Oligonucleotide Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 91. China Oligonucleotide Therapeutics Market Size by Type (2027-2032) & (US$ Million) Table 92. China Oligonucleotide Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 93. China Oligonucleotide Therapeutics Market Size by Application (2027-2032) & (US$ Million) Table 94. Asia Oligonucleotide Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 95. Asia Oligonucleotide Therapeutics Market Size by Type (2027-2032) & (US$ Million) Table 96. Asia Oligonucleotide Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 97. Asia Oligonucleotide Therapeutics Market Size by Application (2027-2032) & (US$ Million) Table 98. Asia Oligonucleotide Therapeutics Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 99. Asia Oligonucleotide Therapeutics Market Size by Country (2021-2026) Table 100. Asia Oligonucleotide Therapeutics Market Size by Country (2027-2032) Table 101. South America, Middle East & Africa Oligonucleotide Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 102. South America, Middle East & Africa Oligonucleotide Therapeutics Market Size by Type (2027-2032) & (US$ Million) Table 103. South America, Middle East & Africa Oligonucleotide Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 104. South America, Middle East & Africa Oligonucleotide Therapeutics Market Size by Application (2027-2032) & (US$ Million) Table 105. South America, Middle East & Africa Oligonucleotide Therapeutics Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 106. South America, Middle East & Africa Oligonucleotide Therapeutics Market Size by Country (2021-2026) Table 107. South America, Middle East & Africa Oligonucleotide Therapeutics Market Size by Country (2027-2032) Table 108. Research Programs/Design for This Report Table 109. Authors List of This Report Table 110. Secondary Sources Table 111. Primary Sources List of Figures Figure 1. Oligonucleotide Therapeutics Product Image Figure 2. Global Oligonucleotide Therapeutics Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Oligonucleotide Therapeutics Market Share by Type: 2025 VS 2032 Figure 4. Antisense Oligonucleotide Image Figure 5. Aptamer Image Figure 6. Other Image Figure 7. Global Oligonucleotide Therapeutics Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 8. Global Oligonucleotide Therapeutics Market Share by Application: 2025 VS 2032 Figure 9. Neuromuscular Diseases Image Figure 10. ATTR Image Figure 11. Hepatic VOD Image Figure 12. Other Image Figure 13. Global Oligonucleotide Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Oligonucleotide Therapeutics Market Size (2021-2032) & (US$ Million) Figure 15. Global Oligonucleotide Therapeutics Market Share by Region: 2025 VS 2032 Figure 16. Years Considered Figure 17. Global Oligonucleotide Therapeutics Market Share by Players in 2025 Figure 18. Global Top 5 and 10 Oligonucleotide Therapeutics Players Market Share by Revenue in 2025 Figure 19. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Oligonucleotide Therapeutics Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Oligonucleotide Therapeutics Revenue Market Share by Type (2021-2032) Figure 22. Global Oligonucleotide Therapeutics Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Oligonucleotide Therapeutics Revenue Market Share by Application (2021-2032) Figure 24. North America Oligonucleotide Therapeutics Market Size (2021-2032) & (US$ Million) Figure 25. North America Oligonucleotide Therapeutics Market Share by Type (2021-2032) Figure 26. North America Oligonucleotide Therapeutics Market Share by Application (2021-2032) Figure 27. North America Oligonucleotide Therapeutics Market Share by Country (2021-2032) Figure 28. United States Oligonucleotide Therapeutics Market Size (2021-2032) & (US$ Million) Figure 29. Canada Oligonucleotide Therapeutics Market Size (2021-2032) & (US$ Million) Figure 30. Mexico Oligonucleotide Therapeutics Market Size (2021-2032) & (US$ Million) Figure 31. Europe Oligonucleotide Therapeutics Market Size (2021-2032) & (US$ Million) Figure 32. Europe Oligonucleotide Therapeutics Market Share by Type (2021-2032) Figure 33. Europe Oligonucleotide Therapeutics Market Share by Application (2021-2032) Figure 34. Europe Oligonucleotide Therapeutics Market Share by Country (2021-2032) Figure 35. Germany Oligonucleotide Therapeutics Market Size (2021-2032) & (US$ Million) Figure 36. France Oligonucleotide Therapeutics Market Size (2021-2032) & (US$ Million) Figure 37. U.K. Oligonucleotide Therapeutics Market Size (2021-2032) & (US$ Million) Figure 38. Italy Oligonucleotide Therapeutics Market Size (2021-2032) & (US$ Million) Figure 39. Russia Oligonucleotide Therapeutics Market Size (2021-2032) & (US$ Million) Figure 40. Nordic Countries Oligonucleotide Therapeutics Market Size (2021-2032) & (US$ Million) Figure 41. China Oligonucleotide Therapeutics Market Size (2021-2032) & (US$ Million) Figure 42. China Oligonucleotide Therapeutics Market Share by Type (2021-2032) Figure 43. China Oligonucleotide Therapeutics Market Share by Application (2021-2032) Figure 44. Asia Oligonucleotide Therapeutics Market Size (2021-2032) & (US$ Million) Figure 45. Asia Oligonucleotide Therapeutics Market Share by Type (2021-2032) Figure 46. Asia Oligonucleotide Therapeutics Market Share by Application (2021-2032) Figure 47. Asia Oligonucleotide Therapeutics Market Share by Country (2021-2032) Figure 48. Japan Oligonucleotide Therapeutics Market Size (2021-2032) & (US$ Million) Figure 49. South Korea Oligonucleotide Therapeutics Market Size (2021-2032) & (US$ Million) Figure 50. Taiwan Oligonucleotide Therapeutics Market Size (2021-2032) & (US$ Million) Figure 51. Southeast Asia Oligonucleotide Therapeutics Market Size (2021-2032) & (US$ Million) Figure 52. India Oligonucleotide Therapeutics Market Size (2021-2032) & (US$ Million) Figure 53. Australia Oligonucleotide Therapeutics Market Size (2021-2032) & (US$ Million) Figure 54. South America, Middle East & Africa Oligonucleotide Therapeutics Market Size (2021-2032) & (US$ Million) Figure 55. South America, Middle East & Africa Oligonucleotide Therapeutics Market Share by Type (2021-2032) Figure 56. South America, Middle East & Africa Oligonucleotide Therapeutics Market Share by Application (2021-2032) Figure 57. South America, Middle East & Africa Oligonucleotide Therapeutics Market Share by Country (2021-2032) Figure 58. Brazil Oligonucleotide Therapeutics Market Size (2021-2032) & (US$ Million) Figure 59. South Africa Oligonucleotide Therapeutics Market Size (2021-2032) & (US$ Million) Figure 60. Saudi Arabia Oligonucleotide Therapeutics Market Size (2021-2032) & (US$ Million) Figure 61. Turkey Oligonucleotide Therapeutics Market Size (2021-2032) & (US$ Million) Figure 62. Argentina Oligonucleotide Therapeutics Market Size (2021-2032) & (US$ Million) Figure 63. UAE Oligonucleotide Therapeutics Market Size (2021-2032) & (US$ Million) Figure 64. Egypt Oligonucleotide Therapeutics Market Size (2021-2032) & (US$ Million) Figure 65. Chile Oligonucleotide Therapeutics Market Size (2021-2032) & (US$ Million) Figure 66. Research Process Figure 67. Key Executives Interviewed

Scope & coverage.

Types
  • Antisense Oligonucleotide
  • Aptamer
  • Other
Applications
  • Neuromuscular Diseases
  • ATTR
  • Hepatic VOD
  • Other
Companies covered
  • Biogen
  • Sarepta Therapeutics
  • Jazz Pharmaceuticals
  • Bausch & Lomb
  • Alnylam Pharmaceuticals
  • Dynavax Technologies
  • Kastle therapeutics
  • Akcea Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Oligonucleotide Therapeutics Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Antisense Oligonucleotide
  5. 1.2.3 Aptamer
  6. 1.2.4 Other
  7. 1.3 Market Analysis by Application
  8. 1.3.1 Global Oligonucleotide Therapeutics Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  9. 1.3.2 Neuromuscular Diseases
  10. 1.3.3 ATTR
  11. 1.3.4 Hepatic VOD
  12. 1.3.5 Other
  13. 1.4 Global Market Growth Prospects
  14. 1.5 Global Oligonucleotide Therapeutics Growth Trends by Region
  15. 1.5.1 Global Oligonucleotide Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
  16. 1.5.2 Oligonucleotide Therapeutics Market Size by Region (2021-2026)
  17. 1.5.3 Oligonucleotide Therapeutics Market Size by Region (2027-2032)
  18. 1.6 Assumptions and Limitations
  19. 1.7 Study Goals and Objectives
  20. 1.8 Years Considered
2 Global Oligonucleotide Therapeutics Market Dynamics
  1. 2.1 Oligonucleotide Therapeutics Industry Trends
  2. 2.2 Oligonucleotide Therapeutics Industry Drivers
  3. 2.3 Oligonucleotide Therapeutics Industry Opportunities and Challenges
  4. 2.4 Oligonucleotide Therapeutics Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Oligonucleotide Therapeutics Revenue by Company (2021-2026)
  2. 3.2 Global Oligonucleotide Therapeutics Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Oligonucleotide Therapeutics Key Company Head office and Area Served
  4. 3.4 Global Oligonucleotide Therapeutics Company, Product Type & Application
  5. 3.5 Global Oligonucleotide Therapeutics Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Oligonucleotide Therapeutics Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Oligonucleotide Therapeutics Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Oligonucleotide Therapeutics Tier 1, Tier 2, and Tier 3
4 Oligonucleotide Therapeutics Market by Type
  1. 4.1 Global Oligonucleotide Therapeutics Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Oligonucleotide Therapeutics Market Size by Type (2021-2032)
  3. 4.3 Global Oligonucleotide Therapeutics Market Size Share by Type (2021-2032)
5 Oligonucleotide Therapeutics Market by Application
  1. 5.1 Global Oligonucleotide Therapeutics Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Oligonucleotide Therapeutics Market Size by Application (2021-2032)
  3. 5.3 Global Oligonucleotide Therapeutics Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Biogen
  2. 6.1.1 Biogen Company Information
  3. 6.1.2 Biogen Business Overview
  4. 6.1.3 Biogen Oligonucleotide Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Biogen Oligonucleotide Therapeutics Product Portfolio
  6. 6.1.5 Biogen Recent Developments
  7. 6.2 Sarepta Therapeutics
  8. 6.2.1 Sarepta Therapeutics Company Information
  9. 6.2.2 Sarepta Therapeutics Business Overview
  10. 6.2.3 Sarepta Therapeutics Oligonucleotide Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Sarepta Therapeutics Oligonucleotide Therapeutics Product Portfolio
  12. 6.2.5 Sarepta Therapeutics Recent Developments
  13. 6.3 Jazz Pharmaceuticals
  14. 6.3.1 Jazz Pharmaceuticals Company Information
  15. 6.3.2 Jazz Pharmaceuticals Business Overview
  16. 6.3.3 Jazz Pharmaceuticals Oligonucleotide Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Jazz Pharmaceuticals Oligonucleotide Therapeutics Product Portfolio
  18. 6.3.5 Jazz Pharmaceuticals Recent Developments
  19. 6.4 Bausch & Lomb
  20. 6.4.1 Bausch & Lomb Company Information
  21. 6.4.2 Bausch & Lomb Business Overview
  22. 6.4.3 Bausch & Lomb Oligonucleotide Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Bausch & Lomb Oligonucleotide Therapeutics Product Portfolio
  24. 6.4.5 Bausch & Lomb Recent Developments
  25. 6.5 Alnylam Pharmaceuticals
  26. 6.5.1 Alnylam Pharmaceuticals Company Information
  27. 6.5.2 Alnylam Pharmaceuticals Business Overview
  28. 6.5.3 Alnylam Pharmaceuticals Oligonucleotide Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Alnylam Pharmaceuticals Oligonucleotide Therapeutics Product Portfolio
  30. 6.5.5 Alnylam Pharmaceuticals Recent Developments
  31. 6.6 Dynavax Technologies
  32. 6.6.1 Dynavax Technologies Company Information
  33. 6.6.2 Dynavax Technologies Business Overview
  34. 6.6.3 Dynavax Technologies Oligonucleotide Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Dynavax Technologies Oligonucleotide Therapeutics Product Portfolio
  36. 6.6.5 Dynavax Technologies Recent Developments
  37. 6.7 Kastle therapeutics
  38. 6.7.1 Kastle therapeutics Company Information
  39. 6.7.2 Kastle therapeutics Business Overview
  40. 6.7.3 Kastle therapeutics Oligonucleotide Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Kastle therapeutics Oligonucleotide Therapeutics Product Portfolio
  42. 6.7.5 Kastle therapeutics Recent Developments
  43. 6.8 Akcea Therapeutics
  44. 6.8.1 Akcea Therapeutics Company Information
  45. 6.8.2 Akcea Therapeutics Business Overview
  46. 6.8.3 Akcea Therapeutics Oligonucleotide Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Akcea Therapeutics Oligonucleotide Therapeutics Product Portfolio
  48. 6.8.5 Akcea Therapeutics Recent Developments
7 North America
  1. 7.1 North America Oligonucleotide Therapeutics Market Size (2021-2032)
  2. 7.2 North America Oligonucleotide Therapeutics Market Size by Type
  3. 7.2.1 North America Oligonucleotide Therapeutics Market Size by Type (2021-2026)
  4. 7.2.2 North America Oligonucleotide Therapeutics Market Size by Type (2027-2032)
  5. 7.2.3 North America Oligonucleotide Therapeutics Market Share by Type (2021-2032)
  6. 7.3 North America Oligonucleotide Therapeutics Market Size by Application
  7. 7.3.1 North America Oligonucleotide Therapeutics Market Size by Application (2021-2026)
  8. 7.3.2 North America Oligonucleotide Therapeutics Market Size by Application (2027-2032)
  9. 7.3.3 North America Oligonucleotide Therapeutics Market Share by Application (2021-2032)
  10. 7.4 North America Oligonucleotide Therapeutics Market Size by Country
  11. 7.4.1 North America Oligonucleotide Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Oligonucleotide Therapeutics Market Size by Country (2021-2026)
  13. 7.4.3 North America Oligonucleotide Therapeutics Market Size by Country (2027-2032)
  14. 7.4.4 North America Oligonucleotide Therapeutics Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Oligonucleotide Therapeutics Market Size (2021-2032)
  2. 8.2 Europe Oligonucleotide Therapeutics Market Size by Type
  3. 8.2.1 Europe Oligonucleotide Therapeutics Market Size by Type (2021-2026)
  4. 8.2.2 Europe Oligonucleotide Therapeutics Market Size by Type (2027-2032)
  5. 8.2.3 Europe Oligonucleotide Therapeutics Market Share by Type (2021-2032)
  6. 8.3 Europe Oligonucleotide Therapeutics Market Size by Application
  7. 8.3.1 Europe Oligonucleotide Therapeutics Market Size by Application (2021-2026)
  8. 8.3.2 Europe Oligonucleotide Therapeutics Market Size by Application (2027-2032)
  9. 8.3.3 Europe Oligonucleotide Therapeutics Market Share by Application (2021-2032)
  10. 8.4 Europe Oligonucleotide Therapeutics Market Size by Country
  11. 8.4.1 Europe Oligonucleotide Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Oligonucleotide Therapeutics Market Size by Country (2021-2026)
  13. 8.4.3 Europe Oligonucleotide Therapeutics Market Size by Country (2027-2032)
  14. 8.4.4 Europe Oligonucleotide Therapeutics Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Oligonucleotide Therapeutics Market Size (2021-2032)
  2. 9.2 China Oligonucleotide Therapeutics Market Size by Type
  3. 9.2.1 China Oligonucleotide Therapeutics Market Size by Type (2021-2026)
  4. 9.2.2 China Oligonucleotide Therapeutics Market Size by Type (2027-2032)
  5. 9.2.3 China Oligonucleotide Therapeutics Market Share by Type (2021-2032)
  6. 9.3 China Oligonucleotide Therapeutics Market Size by Application
  7. 9.3.1 China Oligonucleotide Therapeutics Market Size by Application (2021-2026)
  8. 9.3.2 China Oligonucleotide Therapeutics Market Size by Application (2027-2032)
  9. 9.3.3 China Oligonucleotide Therapeutics Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Oligonucleotide Therapeutics Market Size (2021-2032)
  2. 10.2 Asia Oligonucleotide Therapeutics Market Size by Type
  3. 10.2.1 Asia Oligonucleotide Therapeutics Market Size by Type (2021-2026)
  4. 10.2.2 Asia Oligonucleotide Therapeutics Market Size by Type (2027-2032)
  5. 10.2.3 Asia Oligonucleotide Therapeutics Market Share by Type (2021-2032)
  6. 10.3 Asia Oligonucleotide Therapeutics Market Size by Application
  7. 10.3.1 Asia Oligonucleotide Therapeutics Market Size by Application (2021-2026)
  8. 10.3.2 Asia Oligonucleotide Therapeutics Market Size by Application (2027-2032)
  9. 10.3.3 Asia Oligonucleotide Therapeutics Market Share by Application (2021-2032)
  10. 10.4 Asia Oligonucleotide Therapeutics Market Size by Country
  11. 10.4.1 Asia Oligonucleotide Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Oligonucleotide Therapeutics Market Size by Country (2021-2026)
  13. 10.4.3 Asia Oligonucleotide Therapeutics Market Size by Country (2027-2032)
  14. 10.4.4 Asia Oligonucleotide Therapeutics Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Oligonucleotide Therapeutics Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Oligonucleotide Therapeutics Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Oligonucleotide Therapeutics Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Oligonucleotide Therapeutics Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Oligonucleotide Therapeutics Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Oligonucleotide Therapeutics Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Oligonucleotide Therapeutics Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Oligonucleotide Therapeutics Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Oligonucleotide Therapeutics Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Oligonucleotide Therapeutics Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Oligonucleotide Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Oligonucleotide Therapeutics Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Oligonucleotide Therapeutics Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Oligonucleotide Therapeutics Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst